基于超声的附件肿块良恶性鉴别模型的外部验证:一项全国性前瞻性多中心研究(IOTA 6期)
该研究在意大利21个中心前瞻性纳入1431例附件肿块患者,验证RMI与IOTA模型(SRRisk、ADNEX、2步策略)的诊断性能。IOTA各模型AUC为0.91-0.92,高于RMI的0.85,且净获益更高。O-RADS各风险组的恶性患病率与预设风险基本吻合。
要点
- 在意大利21个中心1431例患者中,IOTA各模型区分良恶性附件肿块的AUC为0.91-0.92,高于RMI的0.85。
- IOTA各模型在1%至50%风险阈值下净获益均高于RMI。
- O-RADS 2至5组的恶性患病率与预设风险基本吻合,无论使用2步策略还是O-RADS词典。
核心结论
- 在意大利由专家或非专家超声操作者检查的患者中,RMI区分良恶性附件肿瘤的能力低于IOTA模型。
- 所有IOTA模型(包括SRRisk、ADNEX及含或不含CA125的2步策略)能力相似。
- 4个O-RADS风险类别中恶性患病率与指定恶性风险基本吻合,无论使用2步策略还是O-RADS词典。
研究设计与样本
- 多中心前瞻性观察性研究,纳入意大利区域转诊中心和地区医院。
- 2017年5月至2020年3月,从21个意大利中心(10个肿瘤中心、11个非肿瘤中心)连续纳入1431例附件肿块患者。
- 患者由IOTA认证的妇科医生(不同经验水平)行超声检查,并在纳入扫描后<180天接受手术;参考标准为手术切除后组织学。
主要发现
- 组织学显示995例(69.5%)为良性,436例(30.5%)为恶性(115例,8.0%交界性;263例,18.4%原发浸润性;58例,4.1%转移性肿瘤)。
- RMI的AUC为0.85(95%CI 0.81-0.87);所有IOTA模型(SRRisk、含或不含CA125的ADNEX、含或不含CA125的2步策略)AUC范围为0.91(95%CI 0.88-0.93)至0.92(95%CI 0.89-0.94)。
- 所有IOTA模型在1%至50%风险阈值(交换率)下净获益均高于RMI。
- 所有IOTA模型轻微低估恶性风险,但SRRisk低估程度最小。
- 使用2步策略和O-RADS词典计算的4个O-RADS风险类别恶性患病率及95%CI分别为:O-RADS 2为0.97%(95%CI 0.4-2.6)和1.2%(95%CI 0.5-2.9);O-RADS 3为7.2%(95%CI 5.0-10.3)和6.0%(95%CI 3.6-9.6);O-RADS 4为37.9%(95%CI 32.4-43.8)和27.8%(95%CI 23.6-32.5);O-RADS 5为84%(95%CI 79.8-87.4)和83.1%(95%CI 79.0-86.6)。
关键数值与推荐
- O-RADS 2:恶性风险<1%(原文报告患病率0.97%和1.2%)。
- O-RADS 3:恶性风险1%至<10%(原文报告患病率7.2%和6.0%)。
- O-RADS 4:恶性风险10%至<50%(原文报告患病率37.9%和27.8%)。
- O-RADS 5:恶性风险≥50%(原文报告患病率84%和83.1%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The diagnostic performance of the IOTA methods, the O-RADS lexicon, and the RMI has been validated in prospective and retrospective studies, but most validation studies tested the performance in the hands of experienced ultrasound examiners. OBJECTIVE: To prospectively validate the performance of the Risk of Malignancy Index, the International Ovarian Tumor Analysis Simple Rules Risk Model, the International Ovarian Tumor Analysis Assessment of Different NEoplasias in the adneXa model, and the International Ovarian Tumor Analysis 2-step strategy across different types of ultrasound centers in Italy. A retrospective post hoc analysis estimates malignancy prevalence in Ovarian-Adnexal Reporting and Data System risk groups when using the 2-step strategy or the Ovarian-Adnexal Reporting and Data System lexicon. STUDY DESIGN: This is a multicenter prospective observational study including regional referral centers and district hospitals in Italy. METHODS: Consecutive patients with an adnexal mass examined with ultrasound by an International Ovarian Tumor Analysis-certified gynecologist with different levels of expertise were included, provided they underwent surgery <180 days after the inclusion scan. Ultrasound examination was performed transvaginally or transrectally and was supplemented with an abdominal scan when necessary. Reference standard was the histology of the adnexal mass following surgical removal. Discrimination (area under the receiver operating characteristic curve), calibration, and clinical utility were assessed to illustrate the diagnostic performance of the methods. For the retrospective post hoc analysis, we report the prevalence of malignancy in the Ovarian-Adnexal Reporting and Data System risk groups (Ovarian-Adnexal Reporting and Data System 2: risk of malignancy <1%; Ovarian-Adnexal Reporting and Data System 3: risk of malignancy 1% to <10%; Ovarian-Adnexal Reporting and Data System 4: risk of malignancy 10% to <50%; Ovarian-Adnexal Reporting and Data System 5: risk of malignancy ≥50%), with the Ovarian-Adnexal Reporting and Data System risk group assigned using either the 2-step strategy or the Ovarian-Adnexal Reporting and Data System lexicon. RESULTS: Between May 2017 and March 2020, 1431 patients were enrolled from 21 Italian centers (10 oncological and 11 nononcological). Based on histology, 995 (69.5%) tumors were benign and 436 (30.5%) were malignant (115, 8.0% borderline; 263, 18.4% primary invasive; 58, 4.1% metastatic tumors). For Risk of Malignancy Index, the area under the receiver operating characteristic curve was 0.85 (95% confidence interval, 0.81 to 0.87), whereas for all International Ovarian Tumor Analysis models (Simple Rules Risk Model, Assessment of Different NEoplasias in the adneXa with and without CA125, and 2-step strategy with and without CA125), the area under the receiver operating characteristic curves ranged from 0.91 (95% confidence interval, 0.88-0.93) to 0.92 (95% confidence interval, 0.89-0.94). All International Ovarian Tumor Analysis models demonstrated a higher net benefit than Risk of Malignancy Index across risk thresholds (exchange rates) from 1% to 50%. All International Ovarian Tumor Analysis models slightly underestimated the risk of malignancy, but Simple Rules Risk Model showed the least degree of underestimation. The prevalence of malignancy and the corresponding 95% confidence interval in the 4 Ovarian-Adnexal Reporting and Data System risk categories, as calculated using the 2-step strategy and Ovarian-Adnexal Reporting and Data System lexicon, were 0.97% (95% confidence interval, 0.4-2.6) and 1.2% (95% confidence interval, 0.5-2.9) for Ovarian-Adnexal Reporting and Data System 2, 7.2% (95% confidence interval, 5.0-10.3) and 6.0% (95% confidence interval, 3.6-9.6) for Ovarian-Adnexal Reporting and Data System 3, 37.9% (95% confidence interval, 32.4-43.8) and 27.8% (95% confidence interval, 23.6-32.5) for Ovarian-Adnexal Reporting and Data System 4, and 84% (95% confidence interval, 79.8-87.4) and 83.1% (95% confidence interval, 79.0-86.6) for Ovarian-Adnexal Reporting and Data System 5. CONCLUSION: Risk of Malignancy Index had lower ability than the International Ovarian Tumor Analysis models to distinguish between benign and malignant adnexal tumors in patients examined by either expert or nonexpert ultrasound operators in Italy. All the International Ovarian Tumor Analysis models-including Simple Rules Risk Model, Assessment of Different NEoplasias in the adneXa, and the 2-step strategy with or without CA125-had similar ability. The prevalence of malignancy in each of the 4 Ovarian-Adnexal Reporting and Data System risk categories closely matched the assigned malignancy risk regardless of whether the 2-step strategy or Ovarian-Adnexal Reporting and Data System lexicon was used.
引用
- Moro F, Momi M, Ledger A, et al. External validation of ultrasound-based models for differentiating between benign and malignant adnexal masses: a nationwide prospective multicenter study (IOTA phase 6). Am J Obstet Gynecol. 2025. PMID: 40653066. doi:10.1016/j.ajog.2025.07.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。